Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Diamyd Medical to report European Phase III trial results for type 1 diabetes

Diamyd Medical's President and CEO Elisabeth Lindner states in the CEO comments in today's quarterly report that the Company expects to begin reporting the results from the European Phase III trial in type 1 diabetes as planned in late spring 2011.

25 Jan 2011

Functional tests are necessary to understand human disease despite genetic sequencing

Despite what you might have heard, genetic sequencing alone is not enough to understand human disease. Researchers at Duke University Medical Center have shown that functional tests are absolutely necessary to understand the biological relevance of the results of sequencing studies as they relate to disease, using a suite of diseases known as the ciliopathies which can cause patients to have many different traits.

24 Jan 2011

VIVUS holds End-of-Review meeting with FDA for QNEXA NDA

VIVUS, Inc. today announced that it held an End-of-Review meeting with the Food and Drug Administration (FDA) for the New Drug Application (NDA) for QNEXA®, an investigational drug for the treatment of obesity. The meeting occurred on January 19th at the FDA's offices in Maryland and was attended by senior members of the FDA and VIVUS' management and consultants.

21 Jan 2011

Novo Nordisk to appeal against ruling in repaglinide combination patent case

Today, Novo Nordisk announced that Judge Avern Cohn of the US District Court for the Eastern District of Michigan issued an adverse ruling in a patent litigation case regarding Novo Nordisk's US Patent No. 6,677,358. The district court ruled that the patent, which covers the combination use of repaglinide and metformin for the treatment of type 2 diabetes, is invalid and unenforceable.

From Novo Nordisk 20 Jan 2011

Novo Nordisk's new insulin pen for children receives 2010 GOOD DESIGN Award

A 2010 GOOD DESIGN Award has been awarded to Novo Nordisk for NovoPen Echo, the latest innovation in pen development - designed specifically with the needs of children in mind. Judging is made based on product design which is new, visionary and innovative and that may enrich people's lives.

From Novo Nordisk 19 Jan 2011

Scripps Research receives NIH grant to develop therapies for circadian rhythm disorders

The Scripps Research Institute has been awarded $3.17 million over four years to develop compounds that will counteract disruptions of the human biological clock - the circadian rhythm that regulates our patterns of activity and rest over a 24-hour daily cycle.

19 Jan 2011

Study may help develop novel ways to combat lipotoxic cardiomyopathy, related heart disease

A team led by Rolf Bodmer, Ph.D. at Sanford-Burnham Medical Research Institute recently unraveled an alternative pathway to lipotoxic cardiomyopathy in fruit flies - a genetic mechanism that occurs independently of a diet high in fat.

19 Jan 2011

Diabetes increases risk of death in breast cancer patients

Breast cancer patients are nearly 50 percent more likely to die of any cause if they also have diabetes, according to a comprehensive review of research conducted by Johns Hopkins physicians.

18 Jan 2011

Harbor Biosciences signs development agreements for HE2000, HE3235 and HE3286 with CIPI

Harbor BioSciences, Inc., a leader in the development of a proprietary class of adrenal steroid hormones as novel pharmaceuticals, announced it has licensed the research and development and commercialization rights for three of its products, exclusively in the People's Republic of China and Hong Kong, to China State Institute of Pharmaceutical Industry (CIPI).

18 Jan 2011

Mylan receives FDA approval for generic Precose Tablets ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Acarbose Tablets, 25 mg, 50 mg and 100 mg, the generic version of Bayer's Precose® Tablets, a treatment to be used with diet and exercise to improve glycemic control in adults with type 2 diabetes.

18 Jan 2011

Health Canada approves Eli Lilly's BYETTA for treatment of adults with type 2 diabetes

Eli Lilly Canada is pleased to announce the Health Canada approval of BYETTATM for the treatment of adults with type 2 diabetes.

18 Jan 2011

Women with PCOS face high risk of type 2 diabetes due to aberrations in fat tissue

A study from the University of Gothenburg, shows that women with polycystic ovary syndrome (PCOS) have aberrations in their adipose tissue.

17 Jan 2011

14 foods that deliver research-documented benefits to health

With the start of a new year, many of us resolve to better our habits by trying to incorporate more nutritious foods into our diets. An article in the January issue of Food Technology magazine lists 14 foods that deliver research-documented benefits to health.

14 Jan 2011

Researchers discover molecular mechanism behind coffee's protective effect

Coffee, that morning elixir, may give us an early jump-start to the day, but numerous studies have shown that it also may be protective against type 2 diabetes. Yet no one has really understood why.

14 Jan 2011

Exposure to room light prior to bedtime suppresses melatonin levels, increases cancer and diabetes risk: Study

According to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism, exposure to electrical light between dusk and bedtime strongly suppresses melatonin levels and may impact physiologic processes regulated by melatonin signaling, such as sleepiness, thermoregulation, blood pressure and glucose homeostasis.

13 Jan 2011

FibroGen initiates FG-3019 open-label phase 2 study in idiopathic pulmonary fibrosis

FibroGen, Inc. today announced initiation of an open-label phase 2 study to evaluate the safety, tolerability, and efficacy of FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), in individuals with idiopathic pulmonary fibrosis (IPF), a chronic, progressive, fatal lung disease for which there are no FDA-approved therapies.

13 Jan 2011

Obesity in children today may contribute to 2-5 year decline in life expectancy

For the first time in history, the next generation will not live longer, or even as long, as their parents. "Diseases such as Type II diabetes, high blood pressure, heart conditions and joint deterioration - what were once considered 'adult' diseases - are regularly being diagnosed in children, due to the prevalence of obesity," said Jessica Bartfield, MD, internal medicine and medical weight-loss specialist at Gottlieb Memorial Hospital, part of the Loyola University Health System.

13 Jan 2011

BPA more harmful to women with hormonal and fertility imbalances

A recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), found higher Bisphenol A (BPA) levels in women with polycystic ovary syndrome (PCOS) compared to controls. Furthermore, researchers found a statistically significant positive association between male sex hormones and BPA in these women suggesting a potential role of BPA in ovarian dysfunction.

13 Jan 2011

GSK, ChemoCentryx initiate '786 Phase III clinical trial for Crohn's disease

GlaxoSmithKline and ChemoCentryx, announced today that the first patient with Crohn's disease has initiated treatment in the initial pivotal induction study comparing Traficet-EN, now designated GSK1605786 ('786), to placebo.

12 Jan 2011

Scientists find way to prevent early stage pancreatic cancer in research models

Cancer researchers at The Peggy and Charles Stephenson Oklahoma Cancer Center have found a way to stop early stage pancreatic cancer in research models - a result that has far-reaching implications in chemoprevention for high-risk patients.

12 Jan 2011

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Diamyd Medical to report European Phase III trial results for type 1 diabetes

Functional tests are necessary to understand human disease despite genetic sequencing

VIVUS holds End-of-Review meeting with FDA for QNEXA NDA

Novo Nordisk to appeal against ruling in repaglinide combination patent case

Novo Nordisk's new insulin pen for children receives 2010 GOOD DESIGN Award

Scripps Research receives NIH grant to develop therapies for circadian rhythm disorders

Study may help develop novel ways to combat lipotoxic cardiomyopathy, related heart disease

Diabetes increases risk of death in breast cancer patients

Harbor Biosciences signs development agreements for HE2000, HE3235 and HE3286 with CIPI

Mylan receives FDA approval for generic Precose Tablets ANDA

Health Canada approves Eli Lilly's BYETTA for treatment of adults with type 2 diabetes

Women with PCOS face high risk of type 2 diabetes due to aberrations in fat tissue

14 foods that deliver research-documented benefits to health

Researchers discover molecular mechanism behind coffee's protective effect

Exposure to room light prior to bedtime suppresses melatonin levels, increases cancer and diabetes risk: Study

FibroGen initiates FG-3019 open-label phase 2 study in idiopathic pulmonary fibrosis

Obesity in children today may contribute to 2-5 year decline in life expectancy

BPA more harmful to women with hormonal and fertility imbalances

GSK, ChemoCentryx initiate '786 Phase III clinical trial for Crohn's disease

Scientists find way to prevent early stage pancreatic cancer in research models

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in